Synthesis and pharmacological characterization of sila-panamesine, a sila-analogue of the σ receptor ligand panamesine (EMD 57445)

Organometallics

Volumn 25, Issue 22, 2006, Pages 5396-5408

  Ilg, Rainer ^a   Burschka, Christian ^a   Schepmann, Dirk ^b   Wünsch, Bernhard ^b   Tacke, Reinhold ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; HYDROCHLORIC ACID; MASS SPECTROMETERS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH EFFECTS; PHARMACOKINETICS; SOLUTIONS;

PANAMESINE; PHARMACOLOGICAL CHARACTERIZATION; RECEPTOR AFFINITY;

DRUG PRODUCTS;

EID: 33751432534     PISSN: 02767333     EISSN: None     Source Type: Journal    
DOI: 10.1021/om060562c     Document Type: Article

References (46)

1. Prücher, H.; Gottschlich, R.; Haase, A.; Stohrer, M.; Seyfried, C. Bioorg. Med. Chem. Lett. 1992, 2, 165-170.
2. Bartoszyk, G. D.; Bender, H. M.; Hellmann, J.; Schnorr, C.; Seyfried, C. A. CNS Drug Rev. 1996, 2, 175-194.
3. Van Amsterdam, C. (Merck Patent GmbH, Darmstadt, Germany) PCT Int. Pat. Appl. WO 02/30422 A1 (April 18, 2002).
4. Dahmen, N.; Fischer, V.; Hödl, P.; Rujescu, D.; Reuss, S.; Bartoszyk, G. D.; Hiemke, C. Eur. Neuropsychopharmacol. 1996, 6, 237-243.
5. Maj, J.; Rogóż, Z.; Skuza, G.; Mazela, H. Eur. J. Pharmacol. 1996, 315, 235-243.
6. Skuza, G.; Rogóż, Z. Pol. J. Pharmacol. 1997, 49, 329-335.
7. Skuza, G.; Rogöż, Z.; Golembiowska, K. Pol. J. Pharmacol. 1997, 49, 489-493.
8. Skuza, G.; Golembiowska, K.; Wȩdzony, K. Pol. J. Pharmacol. 1998, 50, 61-64.
9. Skuza, G.; Kolasiewicz, W.; Dziedzicka-Wasylewska, M.; Margas, W. Pol. J. Pharmacol. 1998, 50, 399-406.
10. Skuza, G. Pol. J. Pharmacol. 1999, 51, 477-483.
11. Frieboes, R.-M.; Murck, H.; Wiedemann, K.; Holsboer, F.; Steiger, A. Psychopharmacology (Berlin) 1997, 132, 82-88.
12. Frieboes, R.-M.; Murck, H.; Antonijevic, I.; Kraus, T.; Hinze-Seich, D.; Pollmäscher, T.; Steiger, A. Psychopharmacology (Berlin) 1999, 141, 107-110.
13. Grüder, G.; Müler, M.-J.: Andreas, J.; Heydari, N.; Wetzel, H.; Schlösser, R.; Schlegel, S.; Nickel, O.; Eissner, D.; Benkert, O. Psychopharmacology (Berlin) 1999, 146, 81-86.
14. Huber, M. T.; Gotthardt, U.; Schreiber, W.; Krieg, J.-C. Pharmacopsychiatry 1999, 32, 68-72.
15. Müler, M. J.; Grüder, G.; Wetzel, H.; Müller-Siecheneder, F.; Marx-Dannigkeit, P.; Benkert, O. Psychiatry Res. 1999, 89, 275-280.
16. Reviews dealing with sila-substituted drugs: (a) Bains, W.; Tacke, R. Curr. Opin. Drug Discovery Dev. 2003, 6, 526-543.
17. (b) Showell, G. A.; Mills, J. S. Drug Discovery Today 2003, 8, 551-556.
18. (c) Mills, J. S.; Showell, G. A. Expert Opin. Investig, Drugs 2004, 13, 1149-1157.
19. (d) Englebienne, P.; Van Hoonacker, A.; Herst, C. V. Drug Design Rev.-Online 2005, 2, 467-483.
20. Original publications dealing with sila-substituted drugs: (a) Tacke, R.; Merget, M.; Bertermann, R.; Bernd, M.; Beckers, T.; Reissmann, T. Organometallics 2000, 19, 3486-3497.
21. (b) Merget, M.; Günther, K.; Bernd, M.; Günther, E.; Tacke, R. J. Organomet. Chem. 2001, 628, 183-194.
22. (c) Tacke, R.; Kornek, T.; Heinrich, T.; Burschka, C.; Penka, M.; Pülm, M.; Keim, C.; Mutschier, E.; Lambrecht, G. J. Organomet. Chem. 2001, 640, 140-165.
23. (d) Tacke, R.; Handmann, V. I.; Kreutzmann, K.; Keim, C.; Mutschier, E.; Lambrecht, G. Organometallics 2002, 21, 3727-3732.
24. (e) Tacke, R.; Heinrich, T. Silicon Chem. 2002, 1, 35-39.
25. (f) Tacke, R.; Handmann, V. I.; Bertermann, R.; Burschka, C.; Penka, M.; Seyfried, C. Organometallics 2003, 22, 916-924.
26. (g) Heinrich, T.; Burschka, C.; Warneck, J.; Tacke, R. Organometallics 2004, 23, 361-366.
27. (h) Tacke, R.; Heinrich, T.; Bertermann, R.; Burschka, C.; Hamacher, A.; Kassack, M. U. Organometallics 2004, 23, 4468-4477.
28. (i) Tacke, R.; Schmid, T.; Penka, M.; Burschka, C.; Bains, W.; Warneck, J. Organometallics 2004, 23, 4915-4923.
29. (j) Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Fleming, I.; Gaudon, C.; Ivanova, D.; Gronemeyer, H.; Tacke, R. Organometallics 2005, 24, 3192-3199.
30. (k) Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Warneck, J. B. H.; Tacke, R. Organometallics 2006, 25, 1188-1198.
31. (l) Showell, G. A.; Barnes, M. J.; Daiss, J. O.; Mills, J. S.; Montana, J. G.; Tacke, R.; Warneck, J. B. H. Bioorg. Med. Chem. Lett. 2006, 16, 2555-2558.
32. To avoid any confusion, it should be noted that the stereo descriptors for 1a and 1b ((S)-configuration) differ from those for the corresponding hydrochlorides 1ȧHCl and 1ḃHCl ((R)-configuration).
33. Prücher, H.; Böttcher, H.; Seyfried, C.; Haase, A.; Minck, K.-O.; Gottschlich, R. (Merck Patent GmbH Darmstadt, Germany) Pat. Appl. DE 4017211 Al (Decembers, 1991).
34. Hefte, W.; Hunziker, F.; Thoma, K. (Wander AG, Bern, Switzerland) Pat. Appl. DT 2444972 Ar (April 3, 1975).
35. Compound 10 displayed a limited stability; it could be stored at 20°C for a maximum of 24 h.
36. All attempts to grow single crystals of 1b·HCl suitable for X-ray diffraction studies failed.
37. Heinrich, T.; Burschka, C.; Penka, M.; Wagner, B.; Tacke, R. J. Organomet. Chem. 2005, 690, 33-47.
38. The hydrogen-bonding system was analyzed by using the program system PLATON: Spek, A. L. PLATON; University of Utrecht: Utrecht, The Netherlands, 1998.
39. Maier, C. A.; Wünsch, B. J. Med. Chem. 2002, 45, 438-448.
40. Bedürftig, S.: Wünsch, B. Eur. J. Med. Chem. 2006, 41, 387-396.
41. Gates, K. S.; Silverman, R. B. J. Am. Chem. Soc. 1990, 112, 9364-9372.
42. (a) Sheldrick, G. M. SHELXS-97; University of Göttingen: Göttingen, Germany, 1997.
43. (b) Sheldrick, G. M. Acta Crystallogr., Sect. A 1990, 46, 467-473.
44. Sheldrick, G. M. SHELXL-97; University of Göttingen: Göttingen, Germany, 1997.
45. Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099-3108.
46. Bradford, M. M. Anal. Biochem. 1976, 72, 248-254.